Asthma drug gets extended safety check
NCT ID NCT00246922
Summary
This study followed asthma patients for 28 weeks to check the long-term safety of roflumilast, a daily pill. It continued from a previous 24-week study, tracking 150 adults who had already completed that trial. The main goal was to see if the medication remained safe and effective over a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIAL ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nycomed Japan and Mitsubishi Tanabe Pharma Corporation
Osaka, Japan
Conditions
Explore the condition pages connected to this study.